Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...

Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors –– Jost Fischer, Chairman of ...

Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

This article is authored by Dr YK Gupta, president, AIIMS, Jammu and Ankush Kapoor, founder & CEO, Pharma NXT Biotech.

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...